Trials / Completed
CompletedNCT00034879
Iressa Expanded Access Program (EAP)
An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD1839 (Gefitinib) |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2002-05-03
- Last updated
- 2013-01-04
Locations
626 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00034879. Inclusion in this directory is not an endorsement.